Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Allergy and Asthma Reports
Published in: Current Allergy and Asthma Reports 8/2016

01-08-2016 | Rhinitis (JJ Oppenheimer and J Corren, Section Editors)

Botulinum Toxin for Rhinitis

Authors: Cengiz Ozcan, Onur Ismi

Published in: Current Allergy and Asthma Reports | Issue 8/2016

Login to get access

Abstract

Purpose of Review

Rhinitis is a common clinical entity. Besides nasal obstruction, itching, and sneezing, one of the most important symptoms of rhinitis is nasal hypersecretion produced by nasal glands and exudate from the nasal vascular bed. Allergic rhinitis is an IgE-mediated inflammatory reaction of nasal mucosa after exposure to environmental allergens. Idiopathic rhinitis describes rhinitis symptoms that occur after non-allergic, noninfectious irritants. Specific allergen avoidance, topical nasal decongestants, nasal corticosteroids, immunotherapy, and sinonasal surgery are the main treatment options. Because the current treatment modalities are not enough for reducing rhinorrhea in some patients, novel treatment options are required to solve this problem.

Recent Findings

Botulinum toxin is an exotoxin generated by Clostridium botulinum. It disturbs the signal transmission at the neuromuscular and neuroglandular junction by inhibiting the acetylcholine release from the presynaptic nerve terminal. It has been widely used in neuromuscular, hypersecretory, and autonomic nerve system disorders. There have been a lot of published articles concerning the effect of this toxin on rhinitis symptoms. Based on the results of these reports, intranasal botulinum toxin A administration appears to be a safe and effective treatment method for decreasing rhinitis symptoms in rhinitis patients with a long-lasting effect.

Summary

Botulinum toxin type A will be a good treatment option for the chronic rhinitis patients who are resistant to other treatment methods.
Literature
1.•
Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen. Allergy. 2008;63 suppl 86:8–160. This report is about updating the new classification of allergic rhinitis.CrossRefPubMed
2.
International Consensus Report on Diagnosis and Management of Rhinitis. International Rhinitis Management Working Group. Allergy. 1994;49 Suppl 19:1–34.
3.
Ozcan C, Vayisoglu Y, Dogu O, Gorur K. The effect of intranasal injection of botulinum toxin A on the symptoms of vasomotor rhinitis. Am J Otolaryngol. 2006;27:314–8.CrossRefPubMed
4.•
Rohrbach S, Junghans K, Köhler S, Laskawi R. Minimally invasive application of botulinum toxin A in patients with idiopathic rhinitis. Head Face Med. 2009;5:18. This study is the first clinical study presenting the effect of sponge-soaked application of botulinum toxin-A.CrossRefPubMedPubMedCentral
5.•
Bachert C. Persistent rhinitis—allergic or nonallergic? Allergy. 2004;59 Suppl 76:11–5. This review outlines how to differentiate allergic rhinitis from the non-allergic rhinitis and what is important to diagnose non-allergic rhinitis.CrossRefPubMed
6.•
Shaari CM, Sanders I, Wu BL, Biller HF. Rhinorrhea is decreased in dogs after nasal application of botulinum toxin. Otolaryngol Head Neck Surg. 1995;112:566–71. This experimental study firstly showed the effect of BTX-A on nasal secretion.PubMed
7.
8.
Ismi O, Ozcan C, Karabacak T, et al. Local of neurotrophin-3 in neuronal inflammation of allergic rhinitis: preliminary report. Balk Med J. 2015;32:364–70.CrossRef
9.
Tai CF, Baraniuk JM. A tale of two neurons in the upper airways: pain versus itch. Curr Allergy Asthma Rep. 2003;3:215–20.CrossRefPubMed
10.
Laing TA, Laing ME, O’Sullivan ST. Botulinum toxin for treatment of glandular hypersecretory disorders. J Plast Reconstr Aesthet Surg. 2008;61:1024–8.CrossRefPubMed
11.
Bentivoglio AR, Del Grande A, Perracca M, Ialonga T. Clinical differences between botulinum neurotoxin type A and B. Toxicon. 2015;107:77–84.CrossRefPubMed
12.
13.
Naumann M, Jost W. Botulinum toxin treatment of secretory disorders. Mov Disord. 2004;19 suppl 8:137–41.CrossRef
14.
Persaud R, Garas G, Silva S, Stamatoglou C, Chatrath P, Patel K. An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. J R Soc Med Sh Rep. 2013;4:10.PubMedPubMedCentral
15.
Naumann M, Dressler D, Hallett M, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon. 2013;67:141–52.CrossRefPubMed
16.
17.
Wen WD, Yuan F, Wang JL, Hou YP. Botulinum toxin therapy in the ovalbumin-sensitized rat. Neuroimmunomodulation. 2007;14:78–83.CrossRefPubMed
18.
Kim KS, Kim SS, Yoon JH, Han JW. The effect of botulinum toxin type A injection for intrinsic rhinitis. J Laryngol Otol. 1998;112:248–51.CrossRefPubMed
19.
Dykewicz MS, Hamilos DL. Rhinitis and sinusitis. J Allergy Clin Immunol. 2010;125:103–15.CrossRef
20.
Aoishi K, Takahashi H, Hato N, et al. Treatment of allergic rhinitis with intranasal infusion of botulinum toxin type A in mice. 2016; 147:132-6.
21.•
Rohrbach S, Olthoff A, Laskawi R, Giefer B, Götz W. Botulinum toxin type A induces apoptosis in glands of guinea pigs. Ann Otol Rhinol Laryngol. 2001;110:1045–50. This experimental study is the first study showing histological changes especially apoptosis of nasal glands after intranasal botulinum toxin application.CrossRefPubMed
22.
Gunes MS, Kulahli I, Kokoglu K, et al. Evaluation of the effect of intranasal infiltrated botulinum toxin-A on a model of allergic rhinitis in rabbits: an experimental study. Int J Pediatr Otorhinolaryngol. 2016;83:51–6.CrossRefPubMed
23.
Zhu Z, Stone HF, Thach TQ, Garcia L, Ruegg CL. A novel botulinum neurotoxin topical gel: treatment of allergic rhinitis in rats and comparative safety profile. Am J Rhinol Allergy. 2012;26:450–4.CrossRefPubMed
24.
Rohrbach S, Laskawi R. Minimally invasive application of Botulinum toxin type A in nasal hypersecretion. ORL J Otorhinolaryngol Relat Spec. 2001;63:382–4.CrossRefPubMed
25.•
Unal M, Sevim S, Dogu O, Vayisoglu Y, Kanik Y. Effect of botulinum toxin type A on nasal symptoms in patients with allergic rhinitis: a double-blind, placebo-controlled clinical trial. Acta Otolaryngol. 2003;123:1060–3. This report firstly showed the effect of intraturbinal injection of BTX-A in allergic rhinitis patients.CrossRefPubMed
26.
Wang J, Chen F, Meng M, Zhang X, Chen Y, Huang W, et al. The influence of botulinum toxin type A on vasomotor rhinitis and morphological study. [Article in Chinese]. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2003;17:643–5.PubMed
27.
Yang TY, Jung YG, Kim YH, Jang TY. A comparison of the effects of botulinum toxin A and steroid injection on nasal allergy. Otolaryngol Head Neck Surg. 2008;139:367–71.CrossRefPubMed
28.
Sapci T, Yazici S, Evcimik MF, et al. Investigation of the effects of intranasal botulinum toxin type A and ipratropium bromide nasal spray on nasal hypersecretion in idiopathic rhinitis without eosinophilia. Rhinology. 2008;46:45–51.PubMed
29.
Nowak K, Szyfter W. Application of botulinum toxin A in chronic intrinsic rhinitis. [Article in Polish]. Otolaryngol Pol. 2011;65:103–5.CrossRefPubMed
30.•
Braun T, Gürkov R, Kramer MF, Krause E. Septal injection of botulinum neurotoxin A for idiopathic rhinitis: a pilot study. Am J Otolaryngol. 2012;33:64–7. This article showed the effect of nasal septal BTX-A injection in idiopathic rhinitis patients.CrossRefPubMed
31.
Abtahi SM, Hashemi SM, Abtahi SM, Bastani B. Septal injection in comparison with inferior turbinates injection of botulinum toxin A in patients with allergic rhinitis. J Res Med Sci. 2013;18:400–4.PubMedPubMedCentral
32.
Hashemi SM, Okhovat A, Amini S, Pourghasemian M. Comparing the effects of botulinum toxin-A and cetirizine on the treatment of allergic rhinitis. Allergol Int. 2013;62:245–9.CrossRefPubMed
33.
Shemshadi H, Azimian M, Kamrani AAK, Onsori MA. Botulinum toxin type A on an intranasal sponge for chronic allergic rhinitis: randomized clinical trial. Iran Rehabil J. 2013;11:5–11.
34.
Mozafarinia K, Abna M, Khanjani N. Effect of botulinum neurotoxin A injection into the submucoperichondrium of the nasal septum in reducing idiopathic non-allergic rhinitis and persistent allergic rhinitis. Iran J Otorhinolaryngol. 2015;27:253–9.PubMedPubMedCentral
35.
36.
Vayisoglu Y, Ozcan C, Pekdemir H, Gorur K, Pata YS, Camsari A. Autonomic nervous system evaluation using heart rate variability parameters in vasomotor rhinitis patients. J Otolaryngol. 2006;35:338–42.CrossRefPubMed
Metadata
Title
Botulinum Toxin for Rhinitis
Authors
Cengiz Ozcan
Onur Ismi
Publication date
01-08-2016
Publisher
Springer US
Published in
Current Allergy and Asthma Reports / Issue 8/2016
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-016-0636-3

Other articles of this Issue 8/2016

Current Allergy and Asthma Reports 8/2016 Go to the issue

Asthma (WJ Calhoun and V Ortega, Section Editors)

What Ancestry Can Tell Us About the Genetic Origins of Inter-Ethnic Differences in Asthma Expression

Otitis (D Skoner, Section Editor)

Eosinophil ETosis and DNA Traps: a New Look at Eosinophilic Inflammation

Rhinitis (JJ Oppenheimer and J Corren, Section Editors)

Capsaicin for Rhinitis

Asthma (WJ Calhoun and V Ortega, Section Editors)

Airway Microbiota and the Implications of Dysbiosis in Asthma

Occupational Allergies (J Poole, Section Editor)

Hypersensitivity Pneumonitis Due to Metalworking Fluid Aerosols

Asthma (WJ Calhoun and V Ortega, Section Editors)

New Insights Into the Relationship Between Chitinase-3-Like-1 and Asthma